Project Grant R01CA305986
Award Date 8/11/25
Completion Date 7/31/30
Dollars Obligated $617K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Texas, USA
Similar Awards
- The University of Texas MD Anderson Cancer Center was awarded a $932,350 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) on August 15, 2025. The grant will fund a 3-year project titled "An In Situ Tumor Vaccine to Stimulate Antitumor Immunity Against Breast Cancer". The project aims to develop and evaluate an innovative in situ tumor vaccine approach to stimulate the immune system and enhance the body's natural defenses...
- The National Cancer Institute awarded a $421,685 Project Grant to The University of Texas MD Anderson Cancer Center under the Cancer Biology Research Federal Grant Program (CFDA 93.396). The grant supports a research project titled "Pan-Cancer Analysis of Convergent Immunoglobulins from Tumor-Infiltrating B Cells" with an award period from August 1, 2025 to July 31, 2027. The project aims to analyze immunoglobulins from different cancer types in the TCGA database, identify convergent...
- The University of Texas MD Anderson Cancer Center received a $539,453 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to develop a microfluidics-based approach for isolating antigen-specific T cells in non-small cell lung cancer. The research aims to optimize methods for enriching and identifying T cells that recognize and bind to tumor cells, leveraging this platform to predict clinical outcomes. As a sub-award, the...
- The National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) awarded a $1,847,485 Project Grant to The University of Texas MD Anderson Cancer Center to advance next-generation CAR-NK (chimeric antigen receptor-modified natural killer) cell therapies targeting CD5-positive T-cell malignancies. The award, effective September 19, 2025 through August 31, 2029, will support the development and clinical testing of an engineered CAR-NK cell product expressing an anti-CD5 scFv, IL-15 for...
- The University of Texas MD Anderson Cancer Center received a $647,995 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to conduct research on image-guided bidirectional EphB4 agonist-based therapy for ovarian cancer. The award period runs from September 1, 2023 to August 31, 2027. As a leading cancer treatment and research institution, MD Anderson has extensive experience delivering a wide range of cancer-related...
- This $421,685 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Texas MD Anderson Cancer Center supports research to investigate how the LIFR-LCN2 pathway in liver cancer restricts the cytotoxic function of CD8+ T cells, leading to immune evasion and resistance to immunotherapy. The central hypothesis is that loss of LIFR upregulates LCN2 in liver cancer, thereby suppressing the abundance and cytotoxic function of CD8+...
- The Department of the Army Medical Command awarded a $4,275,962 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program to The University of Texas M.D. Anderson Cancer Center (MD Anderson) on September 15, 2024. The grant supports a 4-year research initiative to develop CD79B-targeting CAR T-cell therapy for B-cell lymphomas. MD Anderson, a prominent academic cancer research and treatment institution, will leverage its expertise in immunotherapy,...
- This $566,981 Project Grant was awarded on September 30, 2023 by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to The University of Texas MD Anderson Cancer Center. The funding supports a 3-year research project titled "TARGETING IMMUNE-CHECKPOINT PROTEIN B7-H3 IN ACUTE MYELOID LEUKEMIA" focused on evaluating novel treatments for acute myeloid leukemia. The University of Texas System is the parent organization for MD Anderson Cancer...
- The University of Texas MD Anderson Cancer Center received a $647,998 Project Grant award from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The award will fund research to develop image-guided, bidirectional EphB4 agonist-based therapy for ovarian cancer over a 4-year period from September 1, 2023 to August 31, 2027. MD Anderson, a comprehensive cancer treatment and research center, has extensive experience conducting basic,...
- This Project Grant award from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) will support the "Discovery of Noncanonical Antigens in Triple-Negative Breast Cancer for Development of Novel T Cell Therapies" at the University of Texas MD Anderson Cancer Center in Houston, TX. The $505,071 award, made on February 15, 2025, will fund research aimed at identifying new cancer-specific antigens and developing innovative T cell-based immunotherapies...